TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05377775

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Iliac Stenting
Description: Conventional Implantation of mesh stent in iliac stenosis with high-risk plaques
Study: NCT06317532

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Lifestyle modification advice
Description: All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lifestyle modification advice
Description: All female participants in groups A and B will be provided with lifestyle modification advice, including recommendations such as reducing caffeine intake, limiting salt consumption, decreasing animal fat consumption, quitting smoking, practicing relaxation techniques, applying heat when needed, considering the use of herbal agents, avoiding cold drinks and foods, and opting for loose, cotton clothing.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Functional exercises
Description: Each female in group (B) will perform the exercise program three times a week for eight weeks at the University Women's Health Unit Exercise protocols mainly consist of relaxation, strengthening, stretching, aerobic exercises, pelvic floor muscle strengthening exercises, yoga, and Pilates
Study: NCT05613348

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CD19 CAR T-Cell(CAT19T2)
Description: Drug: Fludarabine， Administered intravenously Drug: Cyclophosphamide， Administered intravenously
Study: NCT05493566

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study: NCT05808179

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Light
Description: Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur every 20 s

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CBT
Description: Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT
Description: Cognitive behavioral therapy including psychoeducation, sleep hygiene, stimulus control, activity scheduling, motivational interviewing

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sham Light
Description: Broad-spectrum white light flashes are \~4000 lux, 2 msec long, occur once
Study: NCT05108545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amphotericin B liposomes
Description: Amphotericin B liposomes for injection, 3 mg/kg, qd, IV
Study: NCT04875559

Intervention type: OTHER
Intervention: Standardised multimodal pain treatment regimen
Description: Preoperatively:~* Paracetamol 1000 mg p.o.~* Celecoxib 400 mg p.o.~* Dexamethasone 12 mg p.o.~Perioperatively:~* Ondansetron 4 mg IV~* Bupivacaine 2.5 mg/mL, 20 mL LIA~* Oxycodone 0.15 mg/kg IV (Oxycodone 0.25 mg/kg for ALND)~Postoperatively:~* Paracetamol 1000 mg p.o. every 6h PRN~* Ibuprofen 400 mg p.o. every 6h (day 1-5) PRN~* Oxycodone 5 mg IV or 10 mg p.o. PRN~* Ondansetron 4 mg IV or p.o. PRN
Study: NCT04347772

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Oral Nutrition Support
Description: Intensive Nutrition Intervention
Study: NCT05332353

Intervention type: DRUG
Intervention: Bacillus Calmette-Guerin
Description: Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.

Intervention type: DRUG
Intervention: Bacillus Calmette-Guerin
Description: Bacillus Calmette-Guerin (BCG) is immunotherapy to prevent recurrence and progression of non muscle invasive bladder cancer.
Study: NCT03811262

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ESP BLOCK
Description: local anesthetic will be injected between transverous process and erector spinae muscle

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PECS BLOCK
Description: local anesthetic will be injected between pectoralis minor and pectoralis major (10 ml) and between pectoralis minor and serratus (20 ml)
Study: NCT05446103

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blood flow restriction training
Description: After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An 40% occlusion pressure is set and subjects perform 4 sets of elbow flexion (30-15-15-15 reps) using 30% of 1 RM

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Sham Blood flow restriction training
Description: After warming up, the load is set at 80% of the predicted 1Repetition Maximum (RM) for elbow flexors. Following each successful repetition, the load is increased by 0.5 to 1kg until patients: fail to execute the exercise through the entire range of motion; used improper form to complete the repetition; needed assistance; reported pain. We will allow a 2-3 min of rest between each attempt to ensure recovery.~The session starts by calculating the arterial occlusion pressure in the standard anatomical position. Participants rest in the standing position for 3-5 minutes before measurement to ensure restoration of blood flow circulation and a cuff is placed in the most proximal part of their dominant upper-limb. BFR application is conducted by using an automatic personalized tourniquet system (Mad-Up Pro, France). An \<20% of occlusion pressure is set and subjects perform 4 sets of 10 reps of elbow flexion using 65% of 1 RM
Study: NCT06235554

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Stimulation
Description: Renal Denervation procedure as per hospital routine practice
Study: NCT05265572

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Domestic Hygiene and household hygiene Intervention
Description: A demonstration on the domestic hygiene intervention will be conducted where participants will be guided on optimal cleaning of windowsills, floors and other surfaces with water and detergent, and advised on appropriate method of cleaning. Participants will be provided with a package of cleaning materials (mop, bucket, detergent, hand wash liquid soap and cloth for wet dusting) which will be used during the demonstration, and retained by participants to facilitate sustainability of the intervention during and after the study. Participants will be further engaged in an educational discussion, with the aid of a specially designed educational pamphlet containing information about health effects potentially associated with dust lead exposure from mine dumps and the personal hygiene and domestic hygiene steps that may be followed to reduce dust lead exposure.
Study: NCT06160271

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET scan of 68Ga-FAPI
Description: Use of a positron emission tomograph equipped with an X-ray scanner (PET/CT), essential for recording images after injection of a positron-emitting radiopharmaceutical (in this study, 68Ga-FAPI-46).
Study: NCT04660045

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acalabrutinib
Description: Acalabrutinib, oral, 100 mg BID, continuous
Study: NCT06222307

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Game-Based Exercises
Description: Week 1: Dough Kneading, Sorting Legumes, Cutting Lines with Scissors, Coloring with Dry Crayons Week 2: Dough Rolling, Scissor Use, Crumpling Paper, Finger Exercises, Tying Knots with Rubber Bands Week 3: Dough Cutting, Dough Rolling, Dough Stretching, Sewing with Needles, Wrapping Thread like a Spool, Sorting Legumes, Untying Knots in String Week 4: Rhythm Exercises, Dough Kneading and Rolling, Scissor Use, Sorting Legumes, Untying Knots in String Week 5: Stringing Beads on Thread, Unlocking, Tearing Paper, Sorting Legumes, Untying Knots in String Week 6: Tying Shoe Laces, Opening-Closing Jar Lids, Sorting Legumes
Study: NCT04960787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Intervention
Description: Watch online educational videos

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Intervention
Description: Watch online educational videos

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Navigation
Description: Meet with CENTS counselor and PAF case manager
Study: NCT06281899

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin 10 mg Tab
Description: Dapagliflozin 10 mg once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg Tab
Description: Dapagliflozin 10 mg once daily
Study: NCT04960787

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT06281899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Low protein diet
Description: Plant based low protein diet (0.6 g/kg IBW)
Study: NCT04781400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone support
Description: Mobile phone support (SMS)
Study: NCT04960787

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Complete questionnaires
Study: NCT06422533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam
Description: Ceftolozane/tazobactam 1.5 g tid IV infusion for 1 hour during 5 to 7 days

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Piperacillin/tazobactam
Description: Piperacillin/tazobactam 4.5 g qid IV infusion for 30 minutes during 5 to 7 days
Study: NCT05923996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: microbotox
Description: Will be treated by single session of microbotox injection

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fractional carbon dioxide laser
Description: Two sessions of the fractional CO2 laser on this side of the face at 4-weeks intervals
Study: NCT04781400

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote service delivery model
Description: ART treatment delivery via a courier service

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Remote service delivery model
Description: ART treatment delivery via a courier service
Study: NCT05573867

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity on prescription
Description: All participants, regardless of group affiliation, receive routine written and verbal information about PSF and information about recommended level of physical activity. Intervention group receive as add on individualized, digital coaching twice a week for 12 weeks with Physical activity on prescription (FaR) to increase physical activity and reduce PSF after stroke.
Study: NCT06419400

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supportive text messages
Description: The intervention group will receive a series of supportive text messages over the 6 month trial period, varying in content and frequency.
Study: NCT05063240

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile phone text messaging plus prospective motivational interviewing
Description: Interactive weekly mobile phone text messaging plus prospective motivational interviewing at study follow up visits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard infant feeding counselling
Description: Standard infant feeding counselling as part of routine practice at primary healthcare facility

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard infant feeding counselling
Description: Standard infant feeding counselling as part of routine practice at primary healthcare facility
Study: NCT05152420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apixaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Description: FXa Inhibitor
Study: NCT06069089

Intervention type: RADIATION
Intervention: Dexa scan
Description: No intervention

Intervention type: RADIATION
Intervention: Dexa scan
Description: No intervention
Study: NCT04270877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Naltrexone Pill
Description: Treatment with LDN for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
Study: NCT05152420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor
Study: NCT04270877

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral tablet
Description: Treatment with LDN-placebo for 12 weeks, including af titration phase of 4 weeks. Initial dosage of 1.5 mg, dose is increased by 1.5 mg every 7th day to 6 mg at week 4. Dosing is increased based on safety and tolerability and delayed increments are allowed. The participants are maintained on the highest tolerable dose for the last 8 weeks of the treatment period.
Study: NCT05152420

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Edoxaban
Description: FXa Inhibitor
Study: NCT06285279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FKC288
Description: The autologous dual target BCMA/CD19-CAR-T cell of this study is obtained by infecting T cells with anti-BCMA/CD19-CAR lentiviral vectors.~Administration method: intravenous infusion； Subjects will be treated with Fludarabine and Cyclophosphamide before cell infusion.
Study: NCT06445751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step Up for STEM and Health Careers (Step Up) game
Description: Step Up for STEM and Health Careers (Step Up) game is an interactive, digital resource to help high school students understand the importance of diversity in STEM and health careers, attain STEM/health career self-efficacy, and help them create an inclusive learning environment for others.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational PowerPoint Presentation on Diversity in STEM Careers
Description: An educational PowerPoint on Diversity in STEM careers to increase adolescents' STEM/health career self-efficacy, and help them create an inclusive learning environment for others.
Study: NCT05513547

Intervention type: OTHER
Group type: OTHER
Intervention: LE protocol 1: exposure to artificial light
Description: Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.

Intervention type: OTHER
Group type: OTHER
Intervention: LE protocol 1: exposure to artificial light
Description: Participants stay in the lab with light mimicking usual office lighting. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.

Intervention type: OTHER
Group type: OTHER
Intervention: LE protocol 2: natural daylight
Description: Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
Study: NCT06172387

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intra-arterial infusion albumin
Description: The experimental group would inject 20% human blood albumin solution into the responsible blood vessel supply area by catheter artery at a dose of 0.6g/kg. The infusion time is 20-30 minutes. All participant will receive mechanical thrombectomy and a standard clinical therapy.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mechanical thrombectomy and a standard clinical therapy
Description: mechanical thrombectomy and a standard clinical therapy

Intervention type: OTHER
Group type: OTHER
Intervention: mechanical thrombectomy and a standard clinical therapy
Description: mechanical thrombectomy and a standard clinical therapy
Study: NCT05513547

Intervention type: OTHER
Group type: OTHER
Intervention: LE protocol 2: natural daylight
Description: Participants spend the same time outdoors in natural daylight. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.

Intervention type: OTHER
Group type: OTHER
Intervention: LE protocol 3: natural daylight with reduced short-wavelength proportions
Description: Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.

Intervention type: OTHER
Group type: OTHER
Intervention: LE protocol 3: natural daylight with reduced short-wavelength proportions
Description: Participants spend the same time outdoors in natural daylight wearing tinted glasses that filter out short-wavelength light proportions. On days 8, 15, and 22, participants start the experimental protocol 5 hours before HBT: questionnaires, behavioural responsiveness (assessed by PVT), saliva samples for melatonin measurements (until HBT and two more following awakening the next day). Participants will go to bed at HBT and get up 8h later in the morning. Their sleep will be assessed with PSG recordings.
Study: NCT06010329

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sutetinib Maleate Capsule
Description: Oral administration
Study: NCT06115460

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral sitagliptin supplementation
Description: oral sitagliptin supplementation for three months
Study: NCT05653427

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amivantamab
Description: Amivantamab will be administered intravenously.
Study: NCT06127407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ivosidenib 500mg
Description: Provided as tablets, taken orally as two 250mg tablets once daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Provided as tablets, taken orally once daily.